352 related articles for article (PubMed ID: 36119528)
1. Tumor vessel co-option: The past & the future.
Cuypers A; Truong AK; Becker LM; Saavedra-García P; Carmeliet P
Front Oncol; 2022; 12():965277. PubMed ID: 36119528
[TBL] [Abstract][Full Text] [Related]
2. The Inhibition of Vessel Co-Option as an Emerging Strategy for Cancer Therapy.
Carrera-Aguado I; Marcos-Zazo L; Carrancio-Salán P; Guerra-Paes E; Sánchez-Juanes F; Muñoz-Félix JM
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255995
[TBL] [Abstract][Full Text] [Related]
3. Different Forms of Tumor Vascularization and Their Clinical Implications Focusing on Vessel Co-option in Colorectal Cancer Liver Metastases.
Haas G; Fan S; Ghadimi M; De Oliveira T; Conradi LC
Front Cell Dev Biol; 2021; 9():612774. PubMed ID: 33912554
[TBL] [Abstract][Full Text] [Related]
4. Molecular differences of angiogenic versus vessel co-opting colorectal cancer liver metastases at single-cell resolution.
Fleischer JR; Schmitt AM; Haas G; Xu X; Zeisberg EM; Bohnenberger H; Küffer S; Teuwen LA; Karras PJ; Beißbarth T; Bleckmann A; Planque M; Fendt SM; Vermeulen P; Ghadimi M; Kalucka J; De Oliveira T; Conradi LC
Mol Cancer; 2023 Jan; 22(1):17. PubMed ID: 36691028
[TBL] [Abstract][Full Text] [Related]
5. Tumor vessel co-option probed by single-cell analysis.
Teuwen LA; De Rooij LPMH; Cuypers A; Rohlenova K; Dumas SJ; García-Caballero M; Meta E; Amersfoort J; Taverna F; Becker LM; Veiga N; Cantelmo AR; Geldhof V; Conchinha NV; Kalucka J; Treps L; Conradi LC; Khan S; Karakach TK; Soenen S; Vinckier S; Schoonjans L; Eelen G; Van Laere S; Dewerchin M; Dirix L; Mazzone M; Luo Y; Vermeulen P; Carmeliet P
Cell Rep; 2021 Jun; 35(11):109253. PubMed ID: 34133923
[TBL] [Abstract][Full Text] [Related]
6. Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma.
Kuczynski EA; Yin M; Bar-Zion A; Lee CR; Butz H; Man S; Daley F; Vermeulen PB; Yousef GM; Foster FS; Reynolds AR; Kerbel RS
J Natl Cancer Inst; 2016 Aug; 108(8):. PubMed ID: 27059374
[TBL] [Abstract][Full Text] [Related]
7. Angiogenesis in NSCLC: is vessel co-option the trunk that sustains the branches?
Coelho AL; Gomes MP; Catarino RJ; Rolfo C; Lopes AM; Medeiros RM; Araújo AM
Oncotarget; 2017 Jun; 8(24):39795-39804. PubMed ID: 26950275
[TBL] [Abstract][Full Text] [Related]
8. Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models.
Bridgeman VL; Vermeulen PB; Foo S; Bilecz A; Daley F; Kostaras E; Nathan MR; Wan E; Frentzas S; Schweiger T; Hegedus B; Hoetzenecker K; Renyi-Vamos F; Kuczynski EA; Vasudev NS; Larkin J; Gore M; Dvorak HF; Paku S; Kerbel RS; Dome B; Reynolds AR
J Pathol; 2017 Feb; 241(3):362-374. PubMed ID: 27859259
[TBL] [Abstract][Full Text] [Related]
9. Pathological features of vessel co-option versus sprouting angiogenesis.
Latacz E; Caspani E; Barnhill R; Lugassy C; Verhoef C; Grünhagen D; Van Laere S; Fernández Moro C; Gerling M; Dirix M; Dirix LY; Vermeulen PB
Angiogenesis; 2020 Feb; 23(1):43-54. PubMed ID: 31655928
[TBL] [Abstract][Full Text] [Related]
10. Vascular co-option in resistance to anti-angiogenic therapy.
Ribatti D; Annese T; Tamma R
Front Oncol; 2023; 13():1323350. PubMed ID: 38148844
[TBL] [Abstract][Full Text] [Related]
11. Generation of vessel co-option lung metastases mouse models for single-cell isolation of metastases-derived cells and endothelial cells.
Cuypers A; Teuwen LA; Bridgeman VL; de Rooij LPMH; Eelen G; Dewerchin M; Cantelmo AR; Kalucka J; Bouché A; Vinckier S; Carton A; Manderveld A; Vermeulen PB; Reynolds AR; Carmeliet P
STAR Protoc; 2022 Dec; 3(4):101691. PubMed ID: 36173713
[TBL] [Abstract][Full Text] [Related]
12. Resistance Mechanisms of Anti-angiogenic Therapy and Exosomes-Mediated Revascularization in Cancer.
Zeng Y; Fu BM
Front Cell Dev Biol; 2020; 8():610661. PubMed ID: 33363174
[TBL] [Abstract][Full Text] [Related]
13. Overview on the Different Patterns of Tumor Vascularization.
Ribatti D; Pezzella F
Cells; 2021 Mar; 10(3):. PubMed ID: 33805699
[TBL] [Abstract][Full Text] [Related]
14. Revisiting tumor angiogenesis: vessel co-option, vessel remodeling, and cancer cell-derived vasculature formation.
Qian CN; Tan MH; Yang JP; Cao Y
Chin J Cancer; 2016 Jan; 35():10. PubMed ID: 26747273
[TBL] [Abstract][Full Text] [Related]
15. Vessel co-option: how tumors obtain blood supply in the absence of sprouting angiogenesis.
Leenders WP; Küsters B; de Waal RM
Endothelium; 2002; 9(2):83-7. PubMed ID: 12200959
[TBL] [Abstract][Full Text] [Related]
16. Vessel co-option and angiotropic extravascular migratory metastasis: a continuum of tumour growth and spread?
Lugassy C; Vermeulen PB; Ribatti D; Pezzella F; Barnhill RL
Br J Cancer; 2022 Apr; 126(7):973-980. PubMed ID: 34987186
[TBL] [Abstract][Full Text] [Related]
17. Vessel co-option and resistance to anti-angiogenic therapy.
Kuczynski EA; Reynolds AR
Angiogenesis; 2020 Feb; 23(1):55-74. PubMed ID: 31865479
[TBL] [Abstract][Full Text] [Related]
18. Broad targeting of angiogenesis for cancer prevention and therapy.
Wang Z; Dabrosin C; Yin X; Fuster MM; Arreola A; Rathmell WK; Generali D; Nagaraju GP; El-Rayes B; Ribatti D; Chen YC; Honoki K; Fujii H; Georgakilas AG; Nowsheen S; Amedei A; Niccolai E; Amin A; Ashraf SS; Helferich B; Yang X; Guha G; Bhakta D; Ciriolo MR; Aquilano K; Chen S; Halicka D; Mohammed SI; Azmi AS; Bilsland A; Keith WN; Jensen LD
Semin Cancer Biol; 2015 Dec; 35 Suppl(Suppl):S224-S243. PubMed ID: 25600295
[TBL] [Abstract][Full Text] [Related]
19. Resistance Mechanisms to Anti-angiogenic Therapies in Cancer.
Haibe Y; Kreidieh M; El Hajj H; Khalifeh I; Mukherji D; Temraz S; Shamseddine A
Front Oncol; 2020; 10():221. PubMed ID: 32175278
[TBL] [Abstract][Full Text] [Related]
20. Vascular Mimicry: A Novel Neovascularization Mechanism Driving Anti-Angiogenic Therapy (AAT) Resistance in Glioblastoma.
Angara K; Borin TF; Arbab AS
Transl Oncol; 2017 Aug; 10(4):650-660. PubMed ID: 28668763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
